GammaTile® for Brain Tumors

(ENDURANCE Trial)

This trial tests GammaTile®, a treatment option for elderly or frail individuals with certain types of brain tumors, specifically malignant gliomas. The goal is to determine if GammaTile® is safe and effective for people with newly diagnosed or recurring brain tumors. Participants should have a measurable brain tumor that doctors believe can be mostly removed through surgery. The treatment targets those with a tumor visible on scans who meet specific surgical criteria. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

Research has shown that GammaTile® is generally safe and well-tolerated. In one study, only 1 out of 74 patients experienced hair loss. Another study found no unexpected results when experienced doctors used it. Early data also suggests that it can be a safe type of radiation therapy for patients with recurring brain tumors. Overall, these findings suggest that GammaTile® has a promising safety profile, especially for those with challenging conditions like gliomas.¹²³⁴⁵

Researchers are excited about GammaTile® for brain tumors because it offers a unique way to deliver radiation therapy directly to the tumor site. Unlike traditional radiation treatments that require multiple hospital visits, GammaTile® is implanted during surgery, providing targeted therapy right where it's needed most. This localized approach helps to minimize exposure to surrounding healthy brain tissue, potentially reducing side effects. Additionally, the immediate delivery of radiation post-surgery may improve outcomes in elderly or frail patients who might not tolerate conventional treatments well.

Research has shown that GammaTile® can help treat brain tumors like glioblastoma. This trial will evaluate GammaTile® in various contexts, including newly diagnosed and recurrent cases of glioblastoma and other malignant gliomas in elderly or frail patients. Studies have found that GammaTile® delivers radiation directly to the tumor, helping to control its growth and potentially improve survival rates. Specifically, for some patients with recurring glioblastoma, previous treatments with GammaTile® resulted in a median survival time of up to 21 months. This is significant because survival rates for these aggressive tumors are usually low. The treatment is promising because it begins working immediately, delivering radiation right after placement during surgery.⁶⁷⁸⁹¹⁰